We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$17.4B
1-Year Est. Return
131.5%
This Fund
S&P 500
This Quarter
Est. Return
+2.27%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
+$337M
(+2%)
Cap. Flow
+$511M
Cap. Flow
% of AUM
2.93%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
93
New
8
Increased
18
Reduced
6
Closed
9
Top Buys
| 1 |
Praxis Precision Medicines
PRAX
|
+$194M |
| 2 |
GRAL
GRAIL Inc
GRAL
|
+$151M |
| 3 |
Insmed
INSM
|
+$127M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$42M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$31.4M |
Top Sells
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$63.8M |
| 2 |
Immunocore
IMCR
|
+$51.4M |
| 3 |
TERN
Terns Pharmaceuticals
TERN
|
+$38.4M |
| 4 |
BioNTech
BNTX
|
+$25.6M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$22M |
Sector Composition
| 1 | Healthcare | 99.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$22.9B
| $2.89B | 16.62% |
30,744,412
+421
| +0% | +$42K |
|
|
ONC
2
BeOne Medicines Ltd
ONC
$31.7B
| $2.61B | 15% |
8,799,053
| – | – |
|
|
3
Insmed
INSM
$23.5B
| $1.21B | 6.97% |
7,421,111
+828,365
| +13% | +$127M |
|
4
Madrigal Pharmaceuticals
MDGL
$12.3B
| $1.12B | 6.44% |
2,141,701
| – | – |
|
5
Acadia Pharmaceuticals
ACAD
$4.33B
| $955M | 5.48% |
42,896,690
| – | – |
|
6
Revolution Medicines
RVMD
$39.2B
| $929M | 5.34% |
9,555,357
+100,000
| +1% | +$10.1M |
|
7
Celcuity
CELC
$5.16B
| $904M | 5.19% |
7,915,792
| – | – |
|
8
Kodiak Sciences
KOD
$2.65B
| $759M | 4.36% |
19,919,186
| – | – |
|
9
Kymera Therapeutics
KYMR
$9.26B
| $721M | 4.14% |
8,657,242
| – | – |
|
10
Summit Therapeutics
SMMT
$11.9B
| $690M | 3.96% |
36,391,063
| – | – |
|
|
11
Praxis Precision Medicines
PRAX
$8.85B
| $565M | 3.24% |
1,753,198
+626,710
| +56% | +$194M |
|
12
Rhythm Pharmaceuticals
RYTM
$7.45B
| $487M | 2.8% |
5,604,483
| – | – |
|
13
Alkermes
ALKS
$8.46B
| $354M | 2.03% |
10,012,267
| – | – |
|
|
GRAL
14
GRAIL Inc
GRAL
$3.09B
| $208M | 1.2% |
4,028,614
+1,943,281
| +93% | +$151M |
|
15
Edgewise Therapeutics
EWTX
$4.25B
| $207M | 1.19% |
6,575,940
| – | – |
|
16
Ionis Pharmaceuticals
IONS
$9.05B
| $154M | 0.88% |
2,047,727
+255,886
| +14% | +$20.2M |
|
17
Kiniksa Pharmaceuticals
KNSA
$4.8B
| $136M | 0.78% |
2,826,246
| – | – |
|
18
Immunovant
IMVT
$7.92B
| $136M | 0.78% |
5,457,881
| – | – |
|
19
Roivant Sciences
ROIV
$25.1B
| $135M | 0.77% |
4,867,723
-687,294
| -12% | -$17.7M |
|
20
IDEAYA Biosciences
IDYA
$3.48B
| $131M | 0.76% |
3,946,515
+327,689
| +9% | +$11M |
|
21
Arrowhead Research
ARWR
$10.2B
| $125M | 0.72% |
1,992,783
-182,862
| -8% | -$11.6M |
|
22
Stoke Therapeutics
STOK
$1.82B
| $109M | 0.62% |
3,336,697
| – | – |
|
23
Immatics
IMTX
$1.29B
| $107M | 0.62% |
10,916,693
-1,177,401
| -10% | -$11.5M |
|
24
AbCellera Biologics
ABCL
$1.98B
| $106M | 0.61% |
30,275,938
+2,750,298
| +10% | +$9.9M |
|
|
ABVX
25
Abivax
ABVX
$11.8B
| $97.5M | 0.56% |
875,796
| – | – |
|
Similar funds
MCM
ASRS
PP
CS
SFA
VMPIC
LA
BCIM